Sildenafil Use in Covid-19 Patients - A Pilot Study
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/01/030533
- Lead Sponsor
- Sardar Vallabh Bhai Patel Covid Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Established case of Covid-19 (RTPCR +ve)
2.Moderate Covid-19 patients (SpO2 90 â?? 94% on room air, RR 24 â?? 30/min) with visible radiographic features of pneumonia
3.Severe Covid-19 patients (SpO2 < 90% on room air, RR >30/min) with visible radiographic features of pneumonia
1.Pregnant and lactating women
2.Patients on Nitrate medications in any form
3.Patients with any malignant tumor
4.Patients with heart ailments including Myocardial Infarction (in < 6 months) or heart failure.
5.Patients with mental illness or stroke ( < 6months)
6.Advanced liver or kidney ailment
7.Patients with known history of severe systemic hypertension especially if uncontrolled
8.Patients with systemic hypotension because of any reason.
9.Patients allergic to Sildenafil
10.Patients already on mechanical ventilation
11.Patients with inability to take drug orally or inability to place Ryleâ??s tube.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To observe Sildenafil effect on Covid-19 progression including clinical findings, oxygenation and radiological findingsTimepoint: Three weeks or hospital discharge or death whichever is first
- Secondary Outcome Measures
Name Time Method 1) To observe Sildenafil effect on inflammatory markers (CRP, D-Dimer, IL-6, Procalcitonin) and need for ventilation <br/ ><br>2)To monitor any adverse events related to Sildenafil use <br/ ><br>Timepoint: Three weeks or hospital discharge or death